Amicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month Low – Time to Sell?

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $8.78 and last traded at $8.75, with a volume of 35093 shares traded. The stock had previously closed at $8.86.

Analyst Upgrades and Downgrades

FOLD has been the subject of several research reports. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Wells Fargo & Company decreased their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Finally, JPMorgan Chase & Co. raised their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Trading Up 2.9 %

The business’s 50-day moving average price is $9.41 and its 200 day moving average price is $10.20. The company has a market cap of $2.73 billion, a P/E ratio of -49.33, a P/E/G ratio of 1.51 and a beta of 0.69. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $26,000. Virtus Fund Advisers LLC acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $29,000. Covestor Ltd lifted its stake in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 2,312 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth about $55,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $59,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.